semaglutide cancer GLP-1s appear to cut risk. Researchers are asking why and how : NPR Popular weight loss, diabetes drugs

However, there is no official FDA guidance mandating lifelong use, and treatment duration remains an individualized clinical decision

Many of our patients at Nusbaum Medical Centers see an initial 5% reduction within the first 12 weeks of treatment

Consider this landmark study from 2011 which has been cited by over 600 other papers

These developments underscore the regulatory challenges facing telehealth companies attempting to capitalize on the growing demand for GLP-1-based treatments, which include both weight loss and diabetes management therapies

Your care team can offer guidance and help ensure your first week of treatment is as comfortable as possible

Clinical Trials Retatrutide is still moving through clinical development, meaning trials are ongoing